REFERENCES
- Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recom-mendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222–235.
- Draft 2001. Australian antiretroviral guidelines. 2001. Internet Communication. http://www.ashm.org.au/uploadFile/GUIDELINES2.pdf
- Carr A, Chuah J, Hudson J, et al. A randomized, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171–1180.
- French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously un-treated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002;3: 177–185.
- Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;19(353):2093–2099.
- Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associ-ated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25–F32.
- Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syn-drome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667.
- Stata Statistical Software. College Station, TX: Stata Corp.; 2002.
- d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. In-sights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.
- Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discon-tinuation of the first highly active antiretroviral therapy regi-men: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS. 200115:1733–1736.
- Australian HIV Observational Database. Time trends in antiretroviral treatment use in Australia, 1997–2000. Ve-nereology. 200114: 162–168.
- Mocroft A, Youle M, Moore A, et al. Reasons for modifica-tion and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 200115: 185–194.
- Melial SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316.
- Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. In press.